

# Geriatric Assessment and the Relation with Mortality and Hospitalizations in Older Patients Starting Dialysis

Ismay N. van Loon<sup>a-c</sup> Namiko A. Goto<sup>d</sup> Franciscus T.J. Boereboom<sup>a, b</sup>  
Michiel L. Bots<sup>e</sup> Ellen K. Hoogeveen<sup>f</sup> Laila Gamadia<sup>g</sup> E.F.H. van Bommel<sup>h</sup>  
P.J.G. van de Ven<sup>i</sup> Caroline E. Douma<sup>j</sup> H.H. Vincent<sup>k</sup> Yvonne C. Schrama<sup>l</sup>  
Joy Lips<sup>m</sup> Machiel A. Siezenga<sup>n</sup> Alferso C. Abrahams<sup>c</sup> Marianne C. Verhaar<sup>c</sup>  
Marije E. Hamaker<sup>o</sup>

<sup>a</sup>Dianet Dialysis Center, Utrecht, The Netherlands; <sup>b</sup>Department of Internal Medicine, Diaconessenhuis Utrecht, Utrecht, The Netherlands; <sup>c</sup>Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands; <sup>d</sup>Department of Geriatrics, Diaconessenhuis Utrecht, Utrecht, The Netherlands; <sup>e</sup>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands; <sup>f</sup>Department of Internal Medicine Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands; <sup>g</sup>Department of Internal Medicine Tergooi Hospital, Hilversum, The Netherlands; <sup>h</sup>Department of Internal Medicine Albert Schweitzer Hospital, Dordrecht, The Netherlands; <sup>i</sup>Department of Internal Medicine Maasstad Hospital, Rotterdam, The Netherlands; <sup>j</sup>Department of Internal Medicine Spaarne Gasthuis, Hoofddorp, The Netherlands; <sup>k</sup>Department of Internal Medicine Antonius Hospital, Nieuwegein, The Netherlands; <sup>l</sup>Department of Internal Medicine St. Franciscus Hospital, Rotterdam, The Netherlands; <sup>m</sup>Department of Internal Medicine Bernhoven Hospital, Uden, The Netherlands; <sup>n</sup>Department of Internal Medicine Gelderse Vallei Hospital, Ede, The Netherlands; <sup>o</sup>Department of Geriatrics University Medical Center Utrecht, Utrecht, The Netherlands

## Keywords

Dialysis · Conservative care · Elderly · Geriatric assessment · Quality of life

## Abstract

**Background and Objectives:** A geriatric assessment (GA) is a structural method for identifying frail patients. The relation of GA findings and risk of death in end-stage kidney disease (ESKD) is not known. The objective of the GA in Older patients starting Dialysis Study was to assess the association of GA at dialysis initiation with early mortality and hospitalization. **Design, Setting, Participants, and Measurements:** Pa-

tients  $\geq 65$  years old were included just prior to dialysis initiation. All participants underwent a GA, including assessment of (instrumental) activities of daily living (ADL), mobility, cognition, mood, nutrition, and comorbidity. In addition, a frailty screening (Fried Frailty Index, [FFI]) was applied. Outcome measures were 6- and 12-month mortality, and 6-month hospitalization. Associations with mortality were assessed with cox-regression adjusting for age, sex, comorbidity burden, smoking, residual kidney function and dialysis modality. Associations with hospitalization were assessed with logistic regression, adjusting for relevant confounders. **Results:** In all, 192 patients were included, mean age  $75 \pm 7$  years, of whom 48% had  $\geq 3$  geriatric impairments and were

considered frail. The FFI screening resulted in 46% frail patients. Mortality rate was 8 and 15% at 6- and 12-months after enrolment, and transplantation rate was 2 and 4% respectively. Twelve-month mortality risk was higher in patients with  $\geq 3$  impairments (hazard ratio [HR] 2.97 [95% CI 1.19–7.45]) compared to less impaired patients. FFI frail patients had a higher risk of 12-month mortality (HR 7.22 [95% CI 2.47–21.13]) and hospitalization (OR 1.93 [95% CI 1.00–3.72]) compared to fit patients. Malnutrition was associated with 12-month mortality, while impaired ADL and depressive symptoms were associated with 12-month mortality and hospitalization. **Conclusions:** Frailty as assessed by a GA is related to mortality in elderly patients with ESKD. Individual components of the GA are related to both mortality and hospitalization. As the GA allows for distinguishing between frail and fit patients initiating dialysis, it is potentially of added value in the decision-making process concerning dialysis initiation.

© 2019 The Author(s)

Published by S. Karger AG, Basel

## Introduction

The chronic kidney disease population is ageing and an increasing number of older patients start with dialysis [1]. Over the past decade the number of octogenarians on dialysis has almost doubled [2]. Approximately half of the octogenarians and nonagenarians starting dialysis will die within 1 year after initiating dialysis and dropout is particularly high early after initiation [2, 3]. As the burden of dialysis can be high in the elderly, nephrologists increasingly face the dilemma whether initiation of dialysis would be appropriate. Older patients with end-stage kidney disease (ESKD) often exhibit impairments across various geriatric domains, such as dependency in activities of daily living (ADLs), mobility impairment, cognitive impairment, depression and malnutrition [4]. Accumulation and interaction of impairment of multiple domains may contribute to increased vulnerability to external stressors, also referred to as the frailty phenotype [5].

Although emerging evidence exists on the relation between frailty and poor outcome, there is no consensus on the definition. While there are many operationalizations of frailty, most stem from 2 major frailty models: the phenotypic frailty model where frailty is seen as the final common pathway of ageing [6] and the cumulative deficits model [7]. In nephrology, the first model using the Fried Frailty criteria, is most often used to assess frailty; this screening tool measures physical reserves, malnutri-

tion and exhaustion, and is associated with increased hospitalizations and mortality after dialysis initiation [6, 8–10]. A broader concept of frailty is the cumulative deficits model that includes impairment across various geriatric domains, such as somatic, functional and psychosocial impairment [11]. By systematically assessing geriatric domains, a geriatric assessment (GA) is an evidenced-based approach to assess this cumulative deficits construct of frailty. In ESKD, although a myriad of studies showed various geriatric impairments are related to poor outcome, no data is available on whether a GA at initiation of dialysis is related to outcome [4]. Whether frailty according to a GA is capable of distinguishing between fit patients and frail patients, in whom the benefits of dialysis do not offset the burden, is not known yet.

The GA in OLder patients starting Dialysis (GOLD) Study was conducted to assess the relation between frailty according to a GA and early mortality and hospitalization in older patients incident to dialysis. In addition, the relation between the individual geriatric impairments and poor outcome was assessed. Finally, we looked at other frailty instruments and poor outcome.

## Methods

### *Study Design and Patient Selection*

The GOLD study is a multicentre, prospective, cohort study assessing the relation between a GA and poor outcome in ESKD patients. The GOLD study included both patients starting dialysis and patients choosing conservative care. For this analysis we included only the dialysis patients. Participants were enrolled from 17 different hospitals across the Netherlands (Appendix 1) in the period from August 2014 to September 2017. Consecutive patients eligible for dialysis were included between 3 weeks before and 2 weeks after the first dialysis session. Patients were excluded if informed consent was not provided, if they had insufficient understanding of the Dutch language or if they suffered from a terminal non-renal related condition. Patients were followed from start of dialysis until kidney transplantation, death or censoring (recovery kidney function or loss to follow-up). The study was conducted in accordance with the Declaration of Helsinki and approved by the medical ethics review boards of all participating hospitals. Written informed consent was obtained from all patients and participating caregivers prior to enrolment.

### *Data Collection and Analysis*

Baseline demographic data collected from medical charts included age, sex, educational level and living situation, cause of kidney failure, residual renal function, acute start of dialysis, type of dialysis, dialysis access, blood pressure, body mass index and smoking habit.

For the GA, participants were either visited at home (on a non-dialysis day for haemodialysis [HD] patients) or in the dialysis centre, before starting the dialysis session. The assessments were per-

formed by the investigators (I.N.L. or N.A.G.) or by one of the trained research nurses. The GA consisted of validated questionnaires or structured assessments of 7 domains (Appendix 2): (ADL, Katz et al. [12]), instrumental ADL (IADL, Lawton and Brody [13]), mobility (Timed-Up-and-Go [14]), depressive symptoms (Geriatric Depression Scale [15], Appendix 4), nutrition (Mini Nutritional Assessment [16]), comorbidity burden (the Cumulative Illness Rating Scale-Geriatrics) [17, 18] and cognition (Mini-Mental State Examination, [19] Clock drawing test, [20] fluency test [21] and enhanced cued recall test) [22]. Impaired cognition was defined as one or more impaired cognitive tests. The time needed to apply a GA was approximately 1–1.5 h. The outcome of the GA was composed by the sum of impairment in the 7 geriatric domains [23]. Patients were defined as being frail when they had impairments in  $\geq 2$  impairments (GA2+) [23], all patients with  $< 2$  impairments were considered fit. Results of the structured GA were not communicated with the treating physician and therefore did not influence treatment decisions.

In addition, 4 frailty screening methods were applied: Fried Frailty Index (FFI) [6], Groningen Frailty Indicator (GFI) [24], (Appendix 3), the clinical judgment of the nephrologist by means of the “Surprise Question” and the nephrologists’ estimation of the level of frailty. For the Surprise Question, clinicians were asked whether *they would be surprised if the patients would die within 6 months after dialysis initiation* [25]. For the estimation of frailty, the treating nephrologist was asked to indicate how frail the patients was in his/her opinion on a scale from 0 to 10, where 0 was fit and 10 was frail. A score of  $\geq 5$  was a priori defined as frail.

For follow-up, data on 6- and 12-month mortality and 6-month hospitalizations were collected from each centre. The patients who were alive after 6 months were contacted by telephone and asked whether the dialysis therapy was according to (or above) or below their initial expectations.

#### Statistical Analysis

Data is summarized using means with SD, or proportions when appropriate. All domains were dichotomized into impaired and not impaired according to the pre-defined cut-off values (Appendix 2). Differences between groups were assessed using chi-squared tests for dichotomous variables and *t* tests for normally distributed continuous variables.

The relation of the GA and frailty screening methods with mortality was assessed with log rank tests. Factors significantly associated with 12-months mortality (or with a *p* value  $\leq 0.10$ ) were analysed with a cox proportional hazards model, adjusting for age, sex and high comorbidity as defined by the Cumulative Illness Rating Scale-Geriatrics (model 1) and additionally for current smoking, residual renal function and dialysis modality (model 2). Frailty as measured with the GA was a priori defined as having impairments in  $\geq 2$  domains (GA2+) [23]. As none of the patients screened as fit by this definition died, the relation between GA2+ and mortality could not be analysed with a cox-regression model. Thus, we further used  $\geq 3$  impairments (GA3+) for the definition of frailty, and analyzed this accordingly [23]. Due to a low number of deaths, multivariate analysis for 6-month mortality was not performed. Proportional hazards assumptions were assessed using a log-minus-log plot.

A logistic regression analysis was performed for the relation of geriatric impairment with hospitalization (yes/no), adjusted for age, sex and comorbidity burden. A two-tailed *p* < 0.05 was considered statistically significant. Data analysis was performed with SPSS version 22 software [15].

**Table 1.** Baseline characteristics

	<i>n</i> = 192
<b>Demographics</b>	
Age, years, mean $\pm$ SD	75 $\pm$ 7
Gender, male, %	67
<b>Medical history, %</b>	
Hypertension	89
Diabetes mellitus	39
Myocardial infarction	33
Peripheral vascular disease	17
Cerebrovascular event	17
<b>Clinical parameters, %</b>	
Cause of kidney failure	
Renal vascular	50
Diabetes	16
Glomerulonephritis	7
Other	27
Dialysis modality (% PD)	23
Acute start of dialysis, %	16
Access: central venous line (% of HD)	38
BMI, kg/m <sup>2</sup> , mean $\pm$ SD	26 $\pm$ 5
Systolic blood pressure, mm Hg <sup>1</sup> , mean $\pm$ SD	150 $\pm$ 22
Diastolic blood pressure, mm Hg <sup>1</sup> , mean $\pm$ SD	74 $\pm$ 14
eGFR, mL/min/1.73 m <sup>2</sup> CKD-EPI, mean $\pm$ SD	8.0 $\pm$ 3.0
Hemoglobin, mmol/L, mean $\pm$ SD	6.3 $\pm$ 0.9
Albumin, g/L, mean $\pm$ SD	34 $\pm$ 6
Smoking (current), %	14
<b>Social setting, %</b>	
Living alone	42
Living in a nursing home facility	5
University	22
<b>Polypharmacy</b>	
No of drugs, mean $\pm$ SD	11 $\pm$ 5

<sup>1</sup> Pre-dialysis.

PD, peritoneal dialysis; HD haemodialysis, BMI, body mass index.

## Results

### Baseline Characteristics

A total of 196 incident dialysis patients were included in the GOLD Study. Another 28 patients were screened, but excluded because of terminal illness (*n* = 3), language barrier (*n* = 3) or refusal to participate (*n* = 22). The majority of the patients were included just after the start of dialysis (median 8 days, interquartile range 1–13). Four patients were excluded from the prospective analysis because they did not meet the inclusion criteria regarding the interval between time of inclusion and start of dialysis. No patients were lost to follow-up. The mean age was 75 ( $\pm 7$ ) years and 67% of patients were male (Table 1). Impairment across all geriatric domains was common (Table

**Table 2.** Geriatric impairment at baseline

Geriatric impairment	<i>n</i> = 192
Functional impairment, %	
ADL: ≥1 impairment	29
IADL: ≥1 impairment	78
Mobility: severely impaired <sup>a</sup>	18
Cognitive impairment, %	
MMSE <sup>a</sup>	13
Cognitive test battery <sup>#, a</sup>	72
Mood, %	
Depressive symptoms	30
Nutrition, %	
Malnutrition <sup>§</sup>	5
Comorbidities, %	
Severe comorbidity burden <sup>%</sup>	42
Frailty: GA, %	
GA ≥2 impairments	76
GA ≥3 impairments	48
Frailty: screening methods, %	
FFI <sup>a</sup>	46
GFI (≥4)	61
Surprise question (“not surprised”) <sup>b</sup>	23
Clinical impression nephrologist <sup>c</sup>	66

<sup>#</sup> One or more impaired cognitive tests: MMSE, Clock drawing test, fluency test, enhanced cued recall test.

<sup>§</sup> As defined by the Mini Nutritional Assessment.

<sup>%</sup> CIRS-G score ≥2× score 3 or ≥1× score.

<sup>a</sup> <5% missing.

<sup>b</sup> 21% missing.

<sup>c</sup> 22% missing.

ADL, activities of daily living; IADL, instrumental ADL; MMSE, Mini Mental State Examination; GA, geriatric assessment; FFI, Fried Frailty Index; GFI, Groningen Frailty Indicator.

2). Of all patients, 76% had >2 impairments (GA2+) and 48% had ≥3 impairments (GA3+). When frailty-screening tools were applied, the prevalence of frailty ranged from 46% (FFI) to 66% (clinical impression nephrologist).

Of all patients, 77% started HD and 23% peritoneal dialysis (PD). The mean age was lower in the PD group compared to that in the HD group (73 ± 6 vs. 76 ± 7, *p* = 0.04) and PD patients were less likely to live alone (27 vs. 47% of the HD patients, *p* = 0.02). In general, the PD group was less impaired than the HD group, although this did not reach statistical significance (Appendix 5).

### Follow-Up

Follow-up was complete for all patients. The 6-month mortality rate was 8% (*n* = 15, of whom 6 patients [40%] withdrew from dialysis prior to death) and transplantation rate was 2% (*n* = 3), while 12-month mortality rate

was 15% (*n* = 29) and transplantation rate was 4% (*n* = 7). Patients who died within 12 months were older at baseline (mean age 79 ± 7 vs. 75 ± 6 years, *p* < 0.01). Other baseline characteristics did not differ significantly between patients who died and who did not.

### Geriatric Impairment and Mortality

Geriatric impairments were associated with 6- and 12-month mortality (Table 3). Six-month mortality was higher among patients with impairment in IADL (10 vs. 0%, *p* = 0.03), cognitive impairment, as measured with the Mini-Mental State Examination, (20 vs. 6%, *p* = 0.01), depressive symptoms (14 vs. 5%, *p* = 0.04) and malnutrition (30 vs. 7%, *p* < 0.01). Twelve-month mortality was higher among patients with (functional) impairment compared to patients without impairment. In the multivariate analysis, ADL (hazard ratio [HR] 3.20 [95% CI 1.45–7.06]), depressive symptoms (HR 2.30 [95% CI 1.06–5.02]) and malnutrition (HR 4.52 [95% CI 1.40–14.61]) were associated with 12-month mortality (Table 4, model 2). For IADL no events occurred in the fit group, and therefore, a log rank test was applied instead of a cox regression. IADL was significantly associated with 12-month mortality, when stratified for age (<80 and ≥80 years) *p* < 0.01.

### Relation between Frailty and Mortality

GA. Twelve-month mortality rate was 21% among patients with ≥3 impairments (GA3+) and 8% among patients with less impairment (*p* = 0.02). After correcting for potential confounders GA3+ was associated with mortality, HR 2.97 (95% CI 1.19–7.45; Table 4, Model 2). In this model, age was not significantly associated with mortality (HR 1.06 [95% CI 1.00–1.12], *p* = 0.055).

*Frailty screening methods.* Frail patients as measured with the FFI had a higher mortality risk compared to fit patients, with an adjusted HR 4.10 (95% CI 2.47–21.13; Table 4). In addition, the clinical impression of the nephrologist concerning frailty was related to mortality (adjusted HR 7.22 [95% CI 2.47–21.33]). The GFI and the Surprise Question were not related to mortality.

### Hospitalization in the First 6 Months after Dialysis Initiation

During the first 6 months of follow-up, approximately half of the patients (49%) were hospitalized. Patients with impairments in the following geriatric domains were more likely to be hospitalized compared to non-impaired patients when adjusted for potential confounders: ADL (OR 2.88 [95% CI 1.46–5.70]), IADL (OR 2.25 [95% CI 1.07–4.76]), and depressive symptoms (OR 2.29 [95% CI

**Table 3.** Geriatric domains and association with 6- and 12-month mortality

Geriatric impairment	6-Month mortality					12-Month mortality				
	impaired		not impaired		<i>p</i> value	impaired		not impaired		<i>p</i> value
	<i>n</i>	%	<i>n</i>	%		<i>n</i>	%	<i>n</i>	%	
Functional impairment										
ADL: ≥1 impairment	7/57	12	8/135	6	0.13	16/57	28	13/135	10	<0.01
IADL: ≥1 impairment	15/150	10	0/42	0	0.03	29/150	19	0/42	0	<0.01
Mobility: severely impaired <sup>a</sup>	3/35	8	10/148	7	0.71	9/35	26	18/148	12	0.04
Cognitive impairment										
MMSE <sup>a</sup>	5/24	20	10/163	6	0.01	6/24	25	22/136	14	0.14
Cognitive test battery <sup>a</sup>	12/135	9	3/53	6	0.46	21/135	16	7/53	13	0.68
Mood										
Depressive symptoms	8/57	14	7/135	5	0.04	23/99	23	6/93	7	<0.01
Nutrition										
Malnutrition	3/10	30	12/182	7	<0.01	4/10	40	25/182	14	0.02
Comorbidities										
Severe comorbidity burden	7/81	9	8/111	7	0.71	15/81	19	14/111	13	0.26
Frailty: GA	frail		fit		<i>p</i> value	frail		fit		<i>p</i> value
GA ≥2 impairments	15/150	10	0/42	0	0.03	29/150	19	0/42	0	<0.01
GA ≥3 impairments	11/107	10	4/85	6	0.15	22/107	21	7/85	8	0.02
Frailty: screening modalities										
Fried frailty <sup>a</sup>	12/84	14	3/99	3	<0.01	24/84	29	4/99	4	<0.01
GFI (≥4)	10/117	9	5/75	7	0.64	21/117	18	8/75	11	0.17
Surprise question nephrologist <sup>b</sup>	3/35	9	8/117	7	0.73	5/35	14	19/117	16	0.78
Frailty according to nephrologist <sup>c</sup>	8/98	8	3/51	6	0.61	21/98	21	3/51	6	0.01

<sup>a</sup> 5% missing.<sup>b</sup> 21% missing.<sup>c</sup> 22% missing.

ADL, activities of daily living; IADL, instrumental activities of daily living; MMSE, Mini-Mental State Examination; GFI, Groningen Frailty Indicator.

1.21–4.36]). FFI (OR 2.35 [95% CI 1.28–4.30]) and the clinical judgement of frailty by the nephrologist (OR 2.21 [95% CI 1.09–4.46]) were both associated with hospitalization. GA2+, GA3+ and GFI were not. One out of 6 patients reported that the dialysis treatment in the first 6 months after dialysis turned out to be worse than initially expected, while the others reported it to be according to or above expectations. The difference in coping was more pronounced among frail patients: 23% of the FFI-based frail patients reported the treatment to be worse than expected versus 10% among fit patients,  $p = 0.03$ .

## Discussion

In the GOLD Study, we assessed geriatric impairment and frailty in older patients incident to dialysis and their relation with poor outcome. Impairment of the individu-

al geriatric domains ADL, depressive symptoms and malnutrition at the start of dialysis were associated with 1-year mortality. In addition, the cumulative deficits model using the GA was associated with poor outcome. Frail elderly incident dialysis patients with an accumulation of deficits (≥3 geriatric impairments on a GA) were almost 3 times as likely to die within the first year compared to patients with less impairment. In addition, frail patients according to the FFI were >7 times as likely to die within the first year compared to fit patients, and >2 times as likely to be hospitalized.

A GA is recognized as the best clinical practice standard test for the identification of frailty and has been widely adopted in routine elderly care [23]. As far as we know, the relation between frailty according to a GA and mortality has not been established before in elderly dialysis patients. This prognostic information further emphasizes the benefits of using a comprehensive GA (CGA) in

**Table 4.** Geriatric domains and association with 12-month mortality and hospitalizations

Mortality (12 months)	Crude			Adjusted					
	HR	95% CI	<i>p</i> value	model 1 <sup>1</sup>			model 2 <sup>2</sup>		
				HR	95% CI	<i>p</i> value	HR	95% CI	<i>p</i> value
Functional impairment									
ADL: ≥1 impairment	3.00	1.44–6.23	<0.01	3.10	1.43–6.71	<0.01	3.20	1.45–7.06	0.04
IADL: ≥1 impairment	n/a*								
Mobility: severely impaired	2.16	0.97–4.81	0.06	2.04	0.87–4.77	0.10	1.97	0.80–4.85	0.14
Cognitive impairment									
Test battery	1.26	0.53–2.96	0.60						
MMSE	2.13	0.86–5.25	0.10	2.09	0.83–5.24	0.11	2.18	0.85–5.57	0.10
Depressive symptoms	2.39	1.15–4.94	0.02	2.30	1.09–4.84	0.03	2.30	1.06–5.02	0.04
Malnutrition	3.45	1.20–9.91	0.02	4.51	1.45–14.04	0.01	4.52	1.40–14.61	0.01
Severe comorbidity burden	1.05	0.78–1.40	0.77						
Frailty									
GA ≥3 impairments <sup>%</sup>	2.63	1.13–6.17	0.03	2.36	1.12–6.21	0.04	2.97	1.19–7.45	0.02
Fried frailty	8.03	2.78–23.16	<0.01	7.49	2.57–21.83	<0.01	7.22	2.47–21.13	<0.01
GFI (≥4)	1.71	0.76–3.86	0.20						
Surprise question	0.89	0.33–2.39	0.82						
Frailty according nephrologist	3.97	1.18–13.32	0.03	3.88	1.15–13.11	0.03	4.10	1.19–14.14	0.03
Hospitalizations (6 months)									
	Crude			Adjusted <sup>3</sup>					
	OR	95% CI	<i>p</i> value	OR	95% CI	<i>p</i> value			
Functional impairment									
ADL: ≥1 impairment	2.61	1.37–4.96	<0.01	2.63	1.31–5.34	<0.01			
IADL: ≥1 impairment	2.23	1.09–4.56	0.03	2.10	0.99–4.45	0.05			
Mobility: severely impaired	1.90	0.89–4.08	0.10	1.97	0.86–4.50	0.11			
Cognitive impairment									
Test battery	0.65	0.34–1.23	0.19						
MMSE	1.86	0.77–4.50	0.17						
Depressive symptoms	2.35	1.24–4.44	<0.01	2.01	1.05–3.85	0.04			
Malnutrition	1.52	0.41–5.56	0.53						
Severe comorbidity burden	1.24	1.00–1.59	0.09	1.23	0.95–1.59	0.12			
Frailty									
GA ≥3 impairments <sup>%</sup>	1.50	0.84–2.65	0.17						
Fried frailty	2.26	1.15–4.10	<0.01	2.31	1.24–4.32	<0.01			
GFI (≥4)	1.27	0.71–2.67	0.43						
Frailty according nephrologist	2.25	1.12–4.53	0.02	2.35	1.14–4.86	0.02			

<sup>1</sup> Adjusted for age, sex, CIRS-G comorbidity burden.

<sup>2</sup> Adjusted for age, sex, CIRS-G comorbidity burden, smoking, residual renal function and dialysis modality.

<sup>3</sup> Adjusted for age, sex, CIRS-G comorbidity burden.

<sup>%</sup> For the relation with the GA comorbidity was not included in the model, as comorbidity was already captured in the GA.

\* Analysis not applicable, as no events occurred in the non-impaired group.

ADL, activities of daily living; iADL, instrumental activities of daily living; MMSE, Mini Mental State Examination; GFI, Groningen Frailty Indicator; GA, geriatric assessment.

nephrology care. Besides identifying geriatric problems that may inform us on mortality risk, a CGA focuses on a multidisciplinary approach and creating an overall plan for treatment and follow-up [26–28]. In other fields of medicine, a GA contributes to tailor-made care in the el-

derly. A recent systematic review in geriatric oncology showed that after geriatric evaluation, the initial oncologic treatment plan was altered in 28% of patients, mainly towards less invasive treatment, and additional non-oncologic interventions were recommended in the ma-

jority of patients. A positive effect was found on treatment completion and less treatment-related toxicity [29]. Although a CGA has proven beneficial in non-ESKD patients, we do not know yet what effect the CGA has on outcome in patients initiating dialysis [30].

The main disadvantage of a GA is that it is time consuming. Besides, the experience with a GA in nephrology care is sparse so far and it is unclear how, when in the illness trajectory, and how frequently it should be used. Furthermore, several combinations of tools and various models are available for implementation of a GA [23, 31]. As an example, an expert panel of the European Renal Association-European Dialysis Transplant Association and the European Union Geriatric Medicine Society could not endorse one physical functioning test over another [32]. For the assessment of functional status of older patients, the guideline recommended using a simple score to assess functional status, including a self-reported scale and a field test (i.e., sit to stand, gait speed, 6 min walk test). Clinical practice and cross-study comparison would benefit from agreement on uniformity of a certain subset of tests and cut-off values in the nephrology population. The next step would be to assess how to identify patients that would benefit from a GA as a guide for treatment decision-making, or for identifying targets to improve overall quality of life. Whether implementation of a GA in the (pre-) dialysis phase could be (cost-) effective in ESKD patients has to be established as well.

Compared to the cumulative deficits model of frailty, the FFI screening for frailty had a stronger relation with mortality and was associated with hospitalization risk and worse coping. In addition, the FFI is an easy-to-apply screening instrument in clinical practice. The most elaborate aspects are measuring handgrip strength and walking speed, which can be performed within a few minutes if the right tools are available. However, the physical frailty phenotype is not static but may fluctuate over time [33]. Therefore, it should be used with care and conclusions on poor risk should not be made on a single frailty measurement. It may be useful to perform repeated measurements as kidney function declines. While very specific to physical frailty, the sensitivity of FFI to other geriatric impairments that may be relevant to decision making, such as the psychosocial and cognitive domains is poor [34]. Thus, in the context of optimizing personalized care, the FFI provides very limited additional information on the overall health status. Consequently, the role of FFI in the process of decision-making appears limited to screening patients with poor prognosis.

Several clinical scores have been developed to predict short-term mortality, with a moderate to good predictive value [25, 35–37]. Some of these models included geriatric impairment, such as immobility and dementia [25, 35], and assistance with daily living [36], but these impairments were collected registry data and International Statistical Classification of Diseases and Related Health Problems codes. Geriatric impairments usually falls outside traditional disease-oriented care, and as a result are frequently overlooked and not well documented [38, 26, 28]. For example, in a cohort of HD patients, a cognitive test battery revealed severe cognitive impairment in 31% of patients and moderate impairment in 36%, while in <3% the diagnosis cognitive impairment was actually documented in the medical chart [38]. In our study, we found that prospectively assessed impairment in ADL, depressive symptoms and malnutrition at the start of dialysis were associated with 1-year mortality. This is in line with the outcome of previous studies assessing the association between specific geriatric impairments and poor outcome in this population [4]. Interestingly, impairments in these domains can potentially improve with applying interventions [30, 39]. In our study, cognitive impairment was not related to mortality after correction for confounders. This may be explained by the low number of patients and by the fact that we have included mild cognitive impairment instead of (severe) dementia. As our study shows there is a strong relation between geriatric impairments and poor outcome, we advocate expanding the prospective assessment of geriatric impairments in a larger population and assessing the predictive value of geriatric impairment. These factors may be adopted into a more accurate prediction model.

This is the first longitudinal study that focuses on the prognostic value of the cumulative deficits model by means of a GA in incident older dialysis patients. However, some limitations exist. The number of patients was not sufficient to apply a standard multivariate analysis on 6-month mortality, and for 12-month mortality, the model could be adjusted for only a few variables leaving a potential risk of residual confounding. This was due to the fact that overall mortality was lower than expected based on mortality rates reported in other cohorts [35, 37]. Furthermore, this is a selected cohort in which the decision to start dialysis has already been made. Thus, the results cannot directly be extrapolated to the predialysis phase. In addition, as we included mainly Caucasian patients with a relatively low rate of diabetes, our findings may not be fully generalizable to all elderly incident di-

alysis patients. Although it is likely that the GA is related to mortality at the moment of decision-making as well, data are currently lacking. In addition, the cut-off values of the GA for the definition frailty are arbitrary, although patients with  $\geq 2$  or  $\geq 3$  geriatric impairments are generally considered impaired [23].

## Conclusion

This prospective analysis of the GOLD study shows that frailty at the time of dialysis initiation demonstrates a good prognostic value for poor outcome in the elderly, both the cumulative deficits model of frailty, measured with a GA, and the physical frailty model, measured with the FFI, are related to mortality. A GA is capable to distinguish between frail and fit patients initiating dialysis but can also identify potential targets for intervention. Consequently, a GA may be of added value in decision-making in ESKD. Whether the findings of our study can be extrapolated to the pre-dialysis population and whether the actions derived from a GA may improve outcome should be topics of the research agenda in the developing field of geriatric nephrology.

## Acknowledgement

We are grateful to all patients and medical staff who participated in this project. The GA in Older Patients Starting Dialysis Study Investigators: Dianet Dialysis Center: F.T.J.B.; Diakonessenhuis Utrecht: M.E.H.; University Medical Center Utrecht: A.C.A., M.L.B., and M.C.V.; St. Antonius Hospital, Nieuwegein: H.H.V.; Spaarne Gasthuis, Haarlem: C.E.D., C.V.; Bernhoven Hospital, Uden: J. L.; Gelderse Vallei Hospital, Ede: M.A.S.; Ter

## Appendix 1

### *List of participating centres across The Netherlands*

---

Albert Schweitzer Hospital, Dordrecht; Amsterdam University Hospital, Amsterdam; Bernhoven Hospital, Uden, Diakonessenhuis, Utrecht; Groene Hart Hospital, Gouda; Jeroen Bosch Hospital's Hertogenbosch; Spaarne Gasthuis, Hoofddorp, Haarlem; Maastad Hospital, Rotterdam, St. Antonius Hospital, Nieuwegein; St. Elisabeth Hospital, Tilburg; Franciscus Gasthuis & Vlietland hospital, Rotterdam, Schiedam; Ter Gooi Hospital, Hilversum; University Medical Center Utrecht, Utrecht; Zaans Medical Center, Zaandam; Gelderse Vallei Hospital, Ede

---

Gooi Hospital, Hilversum: L.E.G.; Academic Medical Center, Amsterdam: I. Keur; Zaans Medical Center, Zaandam: R.J.L. Klaassen; Jeroen Bosch Hospital, Hertogenbosch: E.K.H.; Albert Schweitzer Hospital, Dordrecht: E.F.H.B.; St. Franciscus Hospital, Rotterdam: Y.C.S.; Maastad Hospital, Rotterdam: P.J.G.V.; and Groene Hart Hospital, Gouda: J.W. Eijgenraam.

## Statement of Ethics

This study complies with the guidelines for human studies and was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.

## Disclosure Statement

The authors have no conflicts of interest. This manuscript had not been published and is not under consideration for publication elsewhere.

## Funding Sources

This work was made possible by Dianet Dialysis Stichting, the Cornelis de Visser Stichting, Stichting Medicina et Scientia, and AstraZeneca. The funding sources had no role in the design, data collection, analysis, manuscript preparation, interpretation, or decision to submit the manuscript for publication.

## Author Contributions

F.T.J.B., E.K.H., L.G., E.F.H.B., P.J.G.V., C.E.D., P.J.G.V., Y.C.S., J.L., M.A.S., A.C.A., and M.C.V. participated in the GOLD study, including data collection. I.N.L., N.A.G., M.L.B., and M.E.H. carried out the present analyses and wrote the draft of the manuscript. F.T.J.B., E.K.H., L.G., E.F.H.B., P.J.G.V., C.E.D., P.J.G.V., Y.C.S., J.L., M.A.S., A.C.A., and M.C.V. critically revised the draft and contributed with comment to improve the manuscript. All authors read and approved the final manuscript.

## Appendix 2

### Geriatric assessment

Domain	Test	Category	Range	Cut-off	Source
ADL	Katz-scale		1–6	≥1	Patient
iADL	Lawton and Brody		1–7	≥1	Patient
Mobility	Timed up and go <sup>&amp;</sup>	Severe		>20 s	Patient
Cognitive impairment	MMSE		0–30	<25	Patient
	Clock		0–14	≤10	
	ECR		0–16	<14	
	Fluency		0–40	<5th percentile <sup>^</sup>	
Depressive symptoms	GDS	<i>No impairment</i>	0–15	<5	Patient
		<i>Mild symptoms</i>		5–10	
		<i>Severe symptoms</i>		>10	
Malnutrition	MNA	<i>Malnutrition</i>	0–30	0–17	Patient
Comorbidities	CIRS-G	Severe <sup>#</sup>			Chart

### Frailty

GA <sup>%</sup>	GA2+	≥2 geriatric impairments	0–7 <sup>%</sup>	(≥2)
	GA3+	≥3 geriatric impairments	0–7 <sup>%</sup>	(≥3)

<sup>%</sup> Sum of impairment in (i)ADL, severe mobility impairment, impairment in ≥ cognitive domain, severe depressive symptoms, malnutrition, severe comorbidity score.

<sup>&</sup> The average of 3 measurements was recorded; immobility was scored as severely impaired.

<sup>^</sup> Corrected for age and education level.

<sup>#</sup> CIRS-G ≥ 2× score 3 or ≥ 1× score 4; renal comorbidity excluded.

GA, Geriatric Assessment; ADL, activities of daily living; (i)ADL, (instrumental) activities of daily living; MMSE, Mini Mental State Examination I; GDS, Geriatric Depression Scale; ECR, Enhanced cued recall; MNA, Mini Nutritional Assessment; CIRS-G, Cumulative Illness Rating Scale Geriatrics.

## Appendix 3

### Frailty screening measurements as used in the study

FFI			
Components	Measurements	Description/cut-off	Score
Malnutrition	Unintentional weight loss	4,5 kg or ≥5%	Yes = 1
Physical performance	Slowness <sup>5</sup>	≥6 seconds/4 meters	Yes = 1
	Low level of physical activity	Last 3 months ≥4 h sedative lifestyle, no activities like cycling or running	Yes = 1
	Grip strength (kg) <sup>#</sup>	Male: <70 year: <28.2; ≥70 year: <21.3 Female: <70 year: <15.4; ≥70 year: <14.7	Yes = 1
General health	Exhaustion	Exhaustion (self-report)	Yes = 1
Frailty: ≥3 points			

GFI		
Components	Description/cut-off	Score
Physical performance	<i>Are you able to carry out these tasks single-handedly and without any help?</i> (The use of help resources, such as a walking stick, walking frame, or wheelchair, is considered to be independent)	Yes = 0, No = 1
General health	1. Shopping	
Neurosensory deficits	2. Walking around outside (around the house or to the neighbours)	
Malnutrition	3. Dressing and undressing	
Polypharmacy	4. Going to the toilet	
Cognition	5. <i>What mark do you give yourself for physical fitness? (scale 010)</i>	0–6 = 1, 7–10 = 0
Mood, psychosocial	6. <i>Do you experience problems in daily life because of poor vision?</i>	Yes = 1, No = 0
	7. <i>Do you experience problems in daily life because of being hard of hearing?</i>	
	8. <i>During the past 6 months have you lost a lot of weight unwillingly?</i> (3 kg in 1 month or 6 kg in 2 months)	Yes = 1, No = 0
	9. <i>Do you take 4 or more different types of medicine?</i>	Yes = 1, No = 0
	10. <i>Do you have any complaints about your memory?</i>	No = 0 Sometimes = 0 Yes = 1
	11. <i>Do you sometimes experience emptiness around you?</i>	No = 0
	12. <i>Do you sometimes miss people around you?</i>	Sometimes = 1
	13. <i>Do you sometimes feel abandoned?</i>	Yes = 1
	14. <i>In the past 4 weeks did you feel downhearted or sad?</i>	No = 0
	15. <i>In the past 4 weeks did you feel nervous or anxious?</i>	Sometimes = 1
Frailty: $\geq 4$ points		

# Grip strength of the dominant hand; best out of three measurements; using electronic hand dynamometer (Model EH101).

% Fastest time of two measurements.

FFI, Fried Frailty Index; GFI, Groningen Frailty Indicator.

## Appendix 4

*Comorbidity burden assessment. CIRS-G [23]. The CIRS-G measures the chronic medical illness burden in the following organ-system categories with a score from 0 to 4. A severe comorbidity burden is defined as a CIRS-G score  $\geq 2 \times$  score 3 or  $\geq 1 \times$  score 4*

Organ systems		
Cardiac	Vascular	Haematological
Respiratory	Ophthalmological and otorhinolaryngology	Upper gastrointestinal
Lower gastrointestinal	Hepatic and pancreatic	Renal <sup>#</sup>
Genitourinary	Musculoskeletal	Neurological
Endocrine	Metabolic and breast	Psychiatric
Score		
0	No problem affecting that system	
1	Current mild problem or past significant problem	
2	Moderate disability or morbidity and/or requires first line therapy	
3	Severe problem and/or constant and significant disability and/or hard to control chronic problems	
4	Extremely severe problem and/or immediate treatment required and/or organ failure and/or severe functional impairment	

# Category renal was excluded in this population with end-stage kidney failure.

CIRS-G, Cumulative Illness Rating Scale – Geriatrics.

## Appendix 5

### Differences baseline between HD and PD

	HD	PD	<i>p</i> value
<i>n</i> (%)	148 (77)	44 (23)	
Demographics			
Age, years, mean ± SD	76±7	73±6	0.04
Male, %	62	84	<0.01
BMI, mean ± SD	27±6	26±7	0.70
University, %	22	21	0.80
Smoking (former, now), %	76	81	0.50
Social setting, %			
Living alone	47	27	0.02
Living in a nursing home facility	6	2	0.32
Drugs, mean ± SD			
No. of drugs	11±4	13±5	0.11
Impairment in geriatric domains, %			
ADL	33	18	0.06
iADL	81	68	0.07
Mobility	21	12	0.15
Cognition	13	11	0.74
Mood	32	23	0.25
Nutrition	54	43	0.21
Comorbidity	43	39	0.59
Frailty, %			
GA ≥2 impairments	79	66	0.07
GA ≥3 impairments	52	36	0.07
Fried	48	38	0.23
GFI	46	27	0.03
Nephrologist frailty	65	70	0.59

HD, haemodialysis; PD, peritoneal dialysis; BMI, body mass index; ADL, activities of daily living; iADL, instrumental ADL; GA, geriatric assessment; GFI, Groningen Frailty Indicator.

## References

- 1 United States renal data system. USRDS. Atlas of ESRD, vol 2, Chapter 1, incidence prevalence patient characteristics & modality. Available from: [http://www.usrds.org/2012/view/v2\\_01.aspx](http://www.usrds.org/2012/view/v2_01.aspx). Accessed 22-08-2016.
- 2 Kurella M, Covinsky KE, Collins AJ, Chertow GM. Octogenarians and nonagenarians starting dialysis in the United States. *Ann Intern Med*. 2007 Feb;146(3):177–83.
- 3 Peeters P, Van Biesen W, Veys N, Lemahieu W, De Moor B, De Meester J. External Validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy. *BMC Nephrol*. 2016 Apr;17(1):41.
- 4 van Loon IN, Wouters TR, Boereboom FT, Bots ML, Verhaar MC, Hamaker ME. The Relevance of Geriatric Impairments in Patients Starting Dialysis: A Systematic Review. *Clin J Am Soc Nephrol*. 2016 Jul;11(7):1245–59.
- 5 Swidler M. Considerations in starting a patient with advanced frailty on dialysis: complex biology meets challenging ethics. *Clin J Am Soc Nephrol*. 2013 Aug;8(8):1421–8.
- 6 Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al.; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci*. 2001 Mar;56(3):M146–56.
- 7 Hamaker ME, Seynaeve C, Wymenga AN, van Tinteren H, Nortier JW, Maartense E, et al. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group. *Breast*. 2014 Feb;23(1):81–7.
- 8 Johansen KL, Delgado C, Bao Y, Kurella Tamura M. Frailty and dialysis initiation. *Se-min Dial*. 2013 Nov-Dec;26(6):690–6.
- 9 Bao Y, Dalrymple L, Chertow GM, Kayser GA, Johansen KL. Frailty, dialysis initiation, and mortality in end-stage renal disease. *Arch Intern Med*. 2012 Jul;172(14):1071–7.
- 10 Iyasere OU, Brown EA, Johansson L, Huson L, Smee J, Maxwell AP, et al. Quality of Life and Physical Function in Older Patients on Dialysis: A Comparison of Assisted Peritoneal Dialysis with Hemodialysis. *Clin J Am Soc Nephrol*. 2016 Mar;11(3):423–30.
- 11 Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. *CMAJ*. 2005 Aug;173(5):489–95.
- 12 Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of Illness in the Aged. The Index of Adl: A Standardized Measure of Biological and Psychosocial Function. *JAMA*. 1963 Sep;185(12):914–9.

- 13 Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist*. 1969; 9(3):179–86.
- 14 Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. *J Am Geriatr Soc*. 1991 Feb; 39(2):142–8.
- 15 Friedman B, Heisel MJ, Delavan RL. Psychometric properties of the 15-item geriatric depression scale in functionally impaired, cognitively intact, community-dwelling elderly primary care patients. *J Am Geriatr Soc*. 2005 Sep;53(9):1570–6.
- 16 Guigoz Y, Vellas B. The Mini Nutritional Assessment (MNA) for grading the nutritional state of elderly patients: presentation of the MNA, history and validation. *Nestle Nutr Workshop Ser Clin Perform Programme*. 1999;1:3–11; discussion 11–2.
- 17 Li M, Tomlinson G, Naglie G, Cook WL, Jassal SV. Geriatric comorbidities, such as falls, confer an independent mortality risk to elderly dialysis patients. *Nephrol Dial Transplant*. 2008 Apr;23(4):1396–400.
- 18 Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. *Psychiatry Res*. 1992 Mar;41(3):237–48.
- 19 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975 Nov;12(3): 189–98.
- 20 Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, et al. Clock drawing in Alzheimer’s disease. A novel measure of dementia severity. *J Am Geriatr Soc*. 1989 Aug;37(8):725–9.
- 21 Canning SJ, Leach L, Stuss D, Ngo L, Black SE. Diagnostic utility of abbreviated fluency measures in Alzheimer disease and vascular dementia. *Neurology*. 2004 Feb;62(4):556–62.
- 22 Saka E, Mihci E, Topcuoglu MA, Balkan S. Enhanced cued recall has a high utility as a screening test in the diagnosis of Alzheimer’s disease and mild cognitive impairment in Turkish people. *Arch Clin Neuropsychol*. 2006 Oct;21(7):745–51.
- 23 Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. *Ann Oncol*. 2015 Jun;26(6):1091–101.
- 24 Peters LL, Boter H, Buskens E, Slaets JP. Measurement properties of the Groningen Frailty Indicator in home-dwelling and institutionalized elderly people. *J Am Med Dir Assoc*. 2012 Jul;13(6):546–51.
- 25 Cohen LM, Ruthazer R, Moss AH, Germain MJ. Predicting six-month mortality for patients who are on maintenance hemodialysis. *Clin J Am Soc Nephrol*. 2010 Jan;5(1):72–9.
- 26 Parlevliet JL, Buurman BM, Pannekeet MM, Boeschoten EM, ten Brinke L, Hamaker ME, et al. Systematic comprehensive geriatric assessment in elderly patients on chronic dialysis: a cross-sectional comparative and feasibility study. *BMC Nephrol*. 2012 May;13(1):30.
- 27 Hall RK, Haines C, Gorbalkin SM, Schlanger L, Shaban H, Schell JO, et al. Incorporating Geriatric Assessment into a Nephrology Clinic: Preliminary Data from Two Models of Care. *J Am Geriatr Soc*. 2016 Oct;64(10): 2154–8.
- 28 Farragher J, Jassal SV. Rehabilitation of the geriatric dialysis patient. *Semin Dial*. 2012 Nov-Dec;25(6):649–56.
- 29 Hamaker ME, Te Molder M, Thielen N, van Munster BC, Schiphorst AH, van Huis LH. The effect of a geriatric evaluation on treatment decisions and outcome for older cancer patients – A systematic review. *J Geriatr Oncol*. 2018 Sep;9(5):430–40.
- 30 Hall RK, McAdams-DeMarco MA. Breaking the cycle of functional decline in older dialysis patients. *Semin Dial*. 2018 Sep;31(5):462–7.
- 31 Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. *J Clin Oncol*. 2014 Aug; 32(24):2595–603.
- 32 Farrington K, Covic A, Nistor I, Aucella F, Clyne N, De Vos L, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR < 45 mL/min/1.73 m<sup>2</sup>): a summary document from the European Renal Best Practice Group. *Nephrol Dial Transplant*. 2017 Jan 1;32(1):9–16.
- 33 Johansen KL, Dalrymple LS, Delgado C, Chertow GM, Segal MR, Chiang J, et al. Factors Associated with Frailty and Its Trajectory among Patients on Hemodialysis. *Clin J Am Soc Nephrol*. 2017 Jul;12(7): 1100–8.
- 34 van Loon IN, Goto NA, Boereboom FT, Bots ML, Verhaar MC, Hamaker ME. Frailty Screening Tools for Elderly Patients Incident to Dialysis. *Clin J Am Soc Nephrol*. 2017 Sep; 12(9):1480–8.
- 35 Couchoud C, Labeeuw M, Moranne O, Allot V, Esnault V, Frimat L, et al.; French Renal Epidemiology and Information Network (REIN) registry. A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease. *Nephrol Dial Transplant*. 2009 May;24(5): 1553–61.
- 36 Thamer M, Kaufman JS, Zhang Y, Zhang Q, Cotter DJ, Bang H. Predicting Early Death Among Elderly Dialysis Patients: Development and Validation of a Risk Score to Assist Shared Decision Making for Dialysis Initiation. *Am J Kidney Dis*. 2015 Dec;66(6):1024–32.
- 37 Wick JP, Turin TC, Faris PD, MacRae JM, Weaver RG, Tonelli M, et al. A Clinical Risk Prediction Tool for 6-Month Mortality After Dialysis Initiation Among Older Adults. *Am J Kidney Dis*. 2017 May;69(5): 568–75.
- 38 Murray AM, Knopman DS. Cognitive impairment in CKD: no longer an occult burden. *Am J Kidney Dis*. 2010 Oct;56(4):615–8.
- 39 Clarkson MJ, Bennett PN, Fraser SF, Warmington SA. Exercise interventions for improving objective physical function in patients with end-stage kidney disease on dialysis: a systematic review and meta-analysis. *Am J Physiol Renal Physiol*. 2019 May 1;316(5): F856–72.